Literature DB >> 22217594

Radiation dose to the fetus from [(18)F]-FDG administration during the second trimester of pregnancy.

Paolo Zanotti-Fregonara1, Thomas M Koroscil, Joseph Mantil, Martin Satter.   

Abstract

The authors estimated the fetal radiation dose from [(18)F]-FDG in a rare case of a woman who underwent a PET/CT scan during the second trimester of pregnancy. The patient, a 27-y-old female with a paraganglioma, received 181.3 MBq [(18)F]-FDG. From the concentrations of radioactivity measured on the images, the time-integrated activity coefficients of the fetus and the placenta were derived. The time-integrated activity coefficients of the mother's organs were taken from the standard values of ICRP publication 106. The final fetal dose was calculated using the 6-mo pregnant model of the OLINDA/EXM software. The fetus showed an overall low and homogeneous [(18)F]-FDG uptake, with an average concentration of 2.41 kBq cm(-3). The uptake in the placenta was generally higher (average concentration = 3.69 kBq cm(-3)). The estimated time-integrated activity coefficients were 0.0130 and 0.0058 Bq h Bq(-1) for the fetus and the placenta, respectively. The final average dose to the fetus was 1.97 × 10(-2) mGy MBq(-1) (3.6 mGy in this patient who received 181.3 MBq). Therefore, the dose to the fetus from [(18)F]-FDG administration during the second trimester of pregnancy is low. When medically indicated, pregnancy should not be a categorical basis for withholding [(18)F]-FDG PET scans.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22217594      PMCID: PMC3253299          DOI: 10.1097/HP.0b013e318226ebb4

Source DB:  PubMed          Journal:  Health Phys        ISSN: 0017-9078            Impact factor:   1.316


  13 in total

1.  Maternal-fetal in vivo imaging: a combined PET and MRI study.

Authors:  Helene Benveniste; Joanna S Fowler; William D Rooney; Daryn H Moller; W Walter Backus; Donald A Warner; Pauline Carter; Payton King; Bruce Scharf; David A Alexoff; Yeming Ma; Paul Vaska; David Schlyer; Nora D Volkow
Journal:  J Nucl Med       Date:  2003-09       Impact factor: 10.057

2.  Proposed addendum to previously published fetal dose estimate tables for 18F-FDG.

Authors:  Michael G Stabin
Journal:  J Nucl Med       Date:  2004-04       Impact factor: 10.057

3.  Use of fluorine-18-labelled deoxyglucose positron emission tomography with computed tomography to localize a paraganglioma in pregnancy.

Authors:  Thomas M Koroscil; Stephen McDonald; Shahan Stutes; Raul J Vila
Journal:  South Med J       Date:  2010-12       Impact factor: 0.954

4.  Do glucose transporters have other roles in addition to placental glucose transport during early pregnancy?

Authors:  Emin Turkay Korgun; Ciler Celik-Ozenci; Yasemin Seval; Gernot Desoye; Ramazan Demir
Journal:  Histochem Cell Biol       Date:  2005-06-18       Impact factor: 4.304

Review 5.  Diagnostic nuclear medicine and risk for the fetus.

Authors:  P Steenvoorde; E K Pauwels; L K Harding; M Bourguignon; B Marière; J J Broerse
Journal:  Eur J Nucl Med       Date:  1998-02

6.  Characterization and expression of human HepG2/erythrocyte glucose-transporter gene.

Authors:  H Fukumoto; S Seino; H Imura; Y Seino; G I Bell
Journal:  Diabetes       Date:  1988-05       Impact factor: 9.461

7.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.

Authors:  Michael G Stabin; Richard B Sparks; Eric Crowe
Journal:  J Nucl Med       Date:  2005-06       Impact factor: 10.057

8.  Estimation of the beta+ dose to the embryo resulting from 18F-FDG administration during early pregnancy.

Authors:  Paolo Zanotti-Fregonara; Christophe Champion; Régine Trébossen; Renaud Maroy; Jean-Yves Devaux; Elif Hindié
Journal:  J Nucl Med       Date:  2008-03-14       Impact factor: 10.057

9.  In vivo quantification of 18f-fdg uptake in human placenta during early pregnancy.

Authors:  Paolo Zanotti-Fregonara; Sebastien Jan; Christophe Champion; Régine Trébossen; Renaud Maroy; Jean-Yves Devaux; Elif Hindié
Journal:  Health Phys       Date:  2009-07       Impact factor: 1.316

10.  Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007.

Authors: 
Journal:  Ann ICRP       Date:  2008
View more
  5 in total

1.  Hodgkin's Disease Staging by FDG PET/CT in a Pregnant Woman.

Authors:  Jérémie Calais; Sébastien Hapdey; Hervé Tilly; Pierre Vera; Mathieu Chastan
Journal:  Nucl Med Mol Imaging       Date:  2014-02-27

2.  The use of PET/CT in pregnancy: A case report of malignant parathyroid carcinoma and a review of the literature.

Authors:  Manpreet Mona Gill; Winnie Sia; Michael Hoskinson; Erin Niven; Rshmi Khurana
Journal:  Obstet Med       Date:  2017-10-09

3.  18F-Fludeoxyglucose Absorbed Dose Estimation in Fetus during Early Pregnancy.

Authors:  Nemat Ahmadi; Alireza Karimian; Mehdi Nasri Nasrabadi
Journal:  J Med Signals Sens       Date:  2022-05-12

Review 4.  Use of Positron Emission Tomography for Pregnancy-Associated Cancer Assessment: A Review.

Authors:  Giulia Parpinel; Maria Elena Laudani; Francesca Paola Giunta; Chiara Germano; Paolo Zola; Bianca Masturzo
Journal:  J Clin Med       Date:  2022-07-01       Impact factor: 4.964

Review 5.  Radiation Absorbed Dose to the Embryo and Fetus from Radiopharmaceuticals.

Authors:  Paolo Zanotti-Fregonara
Journal:  Semin Nucl Med       Date:  2022-01-21       Impact factor: 4.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.